Norges Bank’s Rigel Pharmaceuticals RIGL Stock Holding History

Norges Bank’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-129,506	Closed	-$2.18M	–	1832
2024 Q4	$2.18M	Buy	+129,506	New	+$2.48M	﹤0.01%	1679
2021 Q1	–	Sell	-57,790	Closed	-$2.02M	–	2189
2020 Q4	$2.02M	Buy	+57,790	New	+$1.67M	﹤0.01%	1953
2015 Q1	–	Sell	-42,282	Closed	-$960K	–	2309
2014 Q4	$960K	Hold	42,282	–	–	﹤0.01%	2196
2014 Q3	$821K	Sell	42,282 -42,281	-50%	-$1.19M	﹤0.01%	2220
2014 Q2	$3.07M	Buy	84,563 +15,781	+23%	+$537K	﹤0.01%	2127
2014 Q1	$2.67M	Hold	68,782	–	–	﹤0.01%	2006
2013 Q4	$1.96M	Hold	68,782	–	–	﹤0.01%	2031
2013 Q3	$2.46M	Hold	68,782	–	–	﹤0.01%	2034
2013 Q2	$2.3M	Buy	+68,782	New	+$3.12M	﹤0.01%	2042

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's RIGL Position: Q1 2025 in Review

Norges Bank sold out of Rigel Pharmaceuticals (RIGL) in Q1 2025, closing a stake of 129,506 shares — an estimated $2.18M sold.

Norges Bank first reported a position in RIGL in Q2 2013 and held it in 9 quarters. The position peaked at $3.07M in Q2 2014. 123 funds tracked by Wall St. Rank hold RIGL as of Q1 2025.

Norges Bank reported no remaining Rigel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Norges Bank sold 129,506 Rigel Pharmaceuticals shares in Q1 2025, an estimated $2.18M.
Norges Bank first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Norges Bank's Rigel Pharmaceuticals position peaked at $3.07M in Q2 2014.
123 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.